JP2012526846A5 - - Google Patents

Download PDF

Info

Publication number
JP2012526846A5
JP2012526846A5 JP2012511015A JP2012511015A JP2012526846A5 JP 2012526846 A5 JP2012526846 A5 JP 2012526846A5 JP 2012511015 A JP2012511015 A JP 2012511015A JP 2012511015 A JP2012511015 A JP 2012511015A JP 2012526846 A5 JP2012526846 A5 JP 2012526846A5
Authority
JP
Japan
Prior art keywords
tgf
antibody
human
composition
regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012511015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526846A (ja
JP5834004B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/034741 external-priority patent/WO2010132683A1/en
Publication of JP2012526846A publication Critical patent/JP2012526846A/ja
Publication of JP2012526846A5 publication Critical patent/JP2012526846A5/ja
Application granted granted Critical
Publication of JP5834004B2 publication Critical patent/JP5834004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012511015A 2009-05-13 2010-05-13 ループス治療のための方法および組成物 Active JP5834004B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17792409P 2009-05-13 2009-05-13
US61/177,924 2009-05-13
PCT/US2010/034741 WO2010132683A1 (en) 2009-05-13 2010-05-13 Methods and compositions for treating lupus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014250861A Division JP2015052021A (ja) 2009-05-13 2014-12-11 ループス治療のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2012526846A JP2012526846A (ja) 2012-11-01
JP2012526846A5 true JP2012526846A5 (https=) 2013-06-27
JP5834004B2 JP5834004B2 (ja) 2015-12-16

Family

ID=43085330

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012511015A Active JP5834004B2 (ja) 2009-05-13 2010-05-13 ループス治療のための方法および組成物
JP2014250861A Withdrawn JP2015052021A (ja) 2009-05-13 2014-12-11 ループス治療のための方法および組成物
JP2016197833A Pending JP2017008106A (ja) 2009-05-13 2016-10-06 ループス治療のための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014250861A Withdrawn JP2015052021A (ja) 2009-05-13 2014-12-11 ループス治療のための方法および組成物
JP2016197833A Pending JP2017008106A (ja) 2009-05-13 2016-10-06 ループス治療のための方法および組成物

Country Status (12)

Country Link
US (2) US9617343B2 (https=)
EP (2) EP2429583A4 (https=)
JP (3) JP5834004B2 (https=)
KR (1) KR101800467B1 (https=)
CN (2) CN110179989B (https=)
AU (2) AU2010248935B2 (https=)
BR (1) BRPI1013927A2 (https=)
CA (1) CA2761885A1 (https=)
IL (1) IL216146A0 (https=)
MX (1) MX342907B (https=)
RU (1) RU2607022C2 (https=)
WO (1) WO2010132683A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998405B1 (en) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
US20150073043A1 (en) * 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
RU2019103573A (ru) * 2013-02-08 2019-03-15 Аллегени-Сингер Рисерч Инститьют Клеточно-связанные продукты активации комплемента в качестве диагностических биомаркеров волчанки в доклинической стадии
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP2986990B1 (en) * 2013-03-20 2018-08-15 F.Hoffmann-La Roche Ag Specific detection of rat antibodies in mouse serum
ES3063961T3 (en) 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
JP7237449B2 (ja) * 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体(CARs)の構成およびその使用方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体(CARs)の構成およびその使用方法
CA3287539A1 (en) 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
WO2004042032A2 (en) * 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004226492A1 (en) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor
WO2005042581A2 (en) 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
CN101443040A (zh) * 2006-03-16 2009-05-27 基因技术股份有限公司 用cd4抗体治疗狼疮的方法
CA2648581A1 (en) 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
WO2007121233A1 (en) * 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
GB0608054D0 (en) * 2006-04-24 2006-05-31 Isis Innovation Production and use of regulatory t cells
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
JP2009543579A (ja) * 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのWSX−1/p28
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
EP2998405B1 (en) * 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52

Similar Documents

Publication Publication Date Title
JP2012526846A5 (https=)
RU2011150495A (ru) Способы и композиции для лечения волчанки
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2006501240A5 (https=)
JP2016074740A5 (https=)
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
JP2019521156A5 (https=)
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
JP4272885B2 (ja) コカイン依存症治療用薬剤
JP6770091B2 (ja) ニコチン性アセチルコリン受容体アゴニストによる副鼻腔粘膜疾患を処置するための組成物及び方法
US6288026B1 (en) Process and composition for treating diseases with an oil-in-water emulsion
JP2024541122A (ja) 疾患を治療するための免疫調節性物質を含む医薬組成物およびキット
Ramakrishnan et al. Treatment-related fluctuations in Guillain Barre syndrome and the conundrum of additional cycles of plasmapheresis
RU2403921C1 (ru) Способ комбинированного лечения ограниченной склеродермии с применением локального трансдермального ферментативного электростатического воздействия
CA2364606C (en) Oil-in-water emulsion for the use as medicament or for producing a medicament
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
TWI791425B (zh) 經由皮內(id)途徑投與之組合物之用途
RU2666942C1 (ru) Способ лечения полинейромиопатии критических состояний у реанимационных больных
Feagan et al. P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease
Dreschnack et al. Case Report: Amyotrophic Lateral Sclerosis Treatment with Extracellular Vesicles derived from Mesenchymal Stromal Cells. Medical Research Archives,[online] 13 (9)
JP2019511515A5 (https=)
Osyanina YOUNG PHARMACY-POTENTIAL OF THE FUTURE
Cutter et al. (DXT24) Two Expanded Disability Status Scale Subscales Evaluated in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis.